Atazanavir/cobicistat - BMS/Gilead

Drug Profile

Atazanavir/cobicistat - BMS/Gilead

Alternative Names: Atazanavir sulfate/cobicistat; ATV/GS9350; Evotaz

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Gilead Sciences
  • Class Antiretrovirals; Carbamates; Morpholines; Oligopeptides; Pyridines; Small molecules; Thiazoles; Urea compounds
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 01 Mar 2016 Bristol Myers Squibb completes a phase I pharmacokinetics study in United Kingdom (NCT02589158)
  • 16 Jul 2015 Registered for HIV-1 infections (Combination therapy) in Liechtenstein, Iceland, Norway and European Union (PO)
  • 16 Jul 2015 Updated efficacy and safety data from a phase III trial in HIV-1 infections released by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top